Solifenacin: scientific evidence in the treatment of overactive bladder.
OBJECTIVE
This article aims to analyse the use of solifenacin in the treatment of overactive bladder in order to show its efficacy and safety within the framework of the scientific evidence.


METHODS
The available scientific literature was reviewed, including most of the relevant clinical trials performed with solifenacin.


RESULTS
All the studies analysed show significant improvements in patients treated with solifenacin versus placebo and tolterodine. Efficacy parameters were assessed in objective and subjective terms, with particular emphasis placed on quality of life. Urgency improves in 60% of patients (40 % report no urgency), 58% of patients get continence and 69% perceive an improvement in bladder capacity. On completion of treatment, 80% are satisfied with the results and 79% are willing to continue with the treatment in the long term.


CONCLUSIONS
Solifenacin is effective in the treatment of overactive bladder. The possibility of finding the most effective and tolerable dose with the best response in terms of quality of life constitutes an important difference with regard to other antimuscarinics. The increase to 10 mg gets additional improvements in terms of efficacy, without a significant increase in adverse effects. The side effects perceived were mild or moderate in most cases, and did not lead to more withdrawals compared to placebo. Most patients were satisfied with the treatment and are willing to stay on it in the long term.
Santos
Javier Cambronero
JC
Urodinamic and Functional Urology Unit, Department of Urology, Hospital Infanta Leonor, Madrid, Spain. javicambro@yahoo.es
Telo
Eduardo R Zungri
ER
D002986:Clinical Trials as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D011812:Quinuclidines / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate